Combination therapy shows promise for chronic myeloid leukemia
(University of Texas M. D. Anderson Cancer Center) A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia has revealed potential for not only stopping the disease completely, but also significantly lowering the cost for treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2016 Category: Cancer & Oncology Source Type: news
EUTOS Registry Shows Good CML Outcomes Outside Trials
Data from the large, population-based EUTOS registry showed strong survival outcomes in patients with CML, and validated risk scores as prognostic of outcome. (Source: CancerNetwork)
Source: CancerNetwork - August 30, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Nilotinib, Dasatinib Offer Similar Outcomes in CML Patients
A propensity score –matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
ABCB1 mRNA Could Predict TKI Response in CML
Early evaluation of ABCB1 mRNA expression may help identify CML patients who are likely to be resistant to first- and second-generation tyrosine kinase inhibitors. (Source: CancerNetwork)
Source: CancerNetwork - August 5, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Early detection of leukemia patients' resistance to therapy
Researchers have made a world-first breakthrough in the early detection of patients ' resistance to a common treatment for chronic myeloid leukemia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 28, 2016 Category: Science Source Type: news
Early detection of leukemia patients' resistance to therapy
( < i > University of Adelaide < /i > ) Australian researchers have made a world-first breakthrough in the early detection of patients' resistance to a common treatment for chronic myeloid leukemia, offering some hope that the patients' treatment could be changed sooner to improve their chances of survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 28, 2016 Category: Cancer & Oncology Source Type: news
Long-term dasatinib supported in CML
Dasatinib has durable efficacy and manageable toxicity in the long-term treatment of patients with chronic-phase chronic myeloid leukaemia that is resistant or intolerant to imatinib, shows final analysis of the CA180-034 trial. (Source: MedWire News)
Source: MedWire News - July 22, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
TKI therapy shows ‘excellent efficacy’ in Japanese CML population
A review of tyrosine kinase inhibitor therapy in Japanese patients with chronic myeloid leukaemia demonstrates high rates of treatment response and good outcomes but highlights the various issues associated with treatment discontinuation. (Source: MedWire News)
Source: MedWire News - July 22, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
‘Dramatic’ increase seen in CML life expectancy
Patients with chronic myeloid leukaemia can now expect to live almost as long as members of the general population, say researchers. (Source: MedWire News)
Source: MedWire News - July 22, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
CML patients sustain increased risk of vascular events
Patients treated for chronic myeloid leukaemia have a higher risk of arterial and venous vascular events than their counterparts in the general population, suggest the results of a Swedish cohort study. (Source: MedWire News)
Source: MedWire News - July 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Fighting resistant blood cancer cells
(BIOSS - Centre for Biological Signalling Studies) Around 20 percent of adults diagnosed with leukemia suffer from chronic myeloid leukemia (CML). The protein Gab2 works as an enhancer of cancer-causing signals and is often present in larger quantities in CML cells than in healthy cells. In two studies, Freiburg researchers have made new discoveries concerning the relationship between CML and Gab2 and drugs that can break a particular resistance to Gab2 in CML cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 20, 2016 Category: Global & Universal Source Type: news
Salvage alloSCT remains option for progressing CML patients
Research demonstrates the continuing role of allogeneic stem cell transplantation as a salvage option for patients with chronic myeloid leukaemia who progress to accelerated phase or blast crisis after tyrosine kinase inhibitor failure. (Source: MedWire News)
Source: MedWire News - June 15, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Maintenance TKI therapy ‘feasible’ for high-risk CML patients after allogeneic HSCT
Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe. (Source: MedWire News)
Source: MedWire News - June 15, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Long-term dasatinib findings support first-line use in CML
Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase–chronic myeloid leukaemia. (Source: MedWire News)
Source: MedWire News - June 15, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Tyrosine kinase inhibitors may boost cardiac risk in chronic myeloid leukemia
Patients with chronic myeloid leukemia (CML) who received tyrosine kinase inhibitors (TKIs) had 1.7 times the rate of arterial or venous vascular events of population-based controls in a large... (Source: Family Practice News)
Source: Family Practice News - June 13, 2016 Category: Primary Care Source Type: news
